Combination gene therapy using multiple immunomodulatory genes transferred by a defective infectious single-cycle herpes virus in squamous cell cancer

Cancer Gene Therapy

Volumn 7, Issue 9, 2000, Pages 1279-1285

  Kim, Se Heon ^a   Carew, John F ^b   Kooby, David A ^b   Shields, John ^c   Entwisle, Claire ^a   Patel, Snehal ^b   Shah, Jatin P ^b   Fong, Yuman ^b  

^a Yonsei University College of Medicine   (South Korea)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Cantab Pharmaceuticals Ltd   (United Kingdom)

Author keywords

Defective infectious single cycle virus; Gene therapy; Granulocyte macrophage colony stimulating factor; Squamous cell cancer; Tumor vaccine

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; TUMOR VACCINE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER THERAPY; CONTROLLED STUDY; DEFECTIVE VIRUS; FEMALE; GENE THERAPY; GENE TRANSFER; HERPES VIRUS; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR CELL; TUMOR GROWTH;

ANIMALIA; HERPES; HERPESVIRIDAE; PAPOVAVIRIDAE;

EID: 0033771031     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700231     Document Type: Article

References (41)

1. National cancer data base report on cancer of the head and neck
2. Head and neck cancer
3. Gene therapy for head and neck cancer: Comparing the tumor suppressor gene p53 and a cell cycle regulator WAF1/CIP1(p21)
4. Combination gene therapy for oral cancer in a murine model
5. Interleukin-12 gene therapy prevents establishment of SCCVII squamous cell carcinomas, inhibits tumor growth, and elicits long-term antitumor immunity in syngeneic C3H mice
6. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4
7. Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines
8. Immunotherapy of experimental metastases by vaccination with interleukin gene-transfected adenocarcinoma cells sharing tumor-associated antigens
9. Protective and curative potential of vaccination with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma
10. Experimental and clinical studies of cytokine gene-modified tumor cells
11. Immunotherapy of cancer with modified tumor vaccines
12. Gene therapy in the United States: A five-year status report
13. Clinical promise of tumor immunology
14. The use of HSV-1 vectors to introduce heterologous genes into neurons: Implications for gene therapy
15. Rapid production of interleukin-2-secreting tumor cells by herpes simplex virus-mediated gene transfer: Implications for autologous vaccine production
16. Prevention of hepatic tumor metastases in rats with herpes viral vaccinations and γ-interferon
17. A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cells
18. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease
19. Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV)-2 using a genetically disabled HSV-1
20. Immunotherapy of prostate cancer in the Dunning rat model: Use of cytokine gene-modified tumor vaccines
21. Antitumor effect of granulocyte-macrophage colony-stimulating factor production by melanoma cells
22. Gene transfer as cancer therapy
23. Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells
24. A new immunocompetent murine model for oral cancer
25. Construction and properties of a mutant of herpes simplex virus type 1 with glycoprotein H coding sequences deleted
26. Disabled infectious single-cycle herpes simplex virus as an oncolytic vector for immunotherapy of colorectal cancer
27. Initial proposal of clinical research project: Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for interleukin-2
28. Vaccination with irradiated tumor cells engineered to secret murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
29. Increasing tumor immunogenicity by genetic modification
30. Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-7 cDNAs
31. New strategies for enhancing the immunogenicity of tumors
32. Intefieukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity
33. Immunotherapy via gene therapy: Comparison of the effect of tumor cells transduced with the interleukin-2, intefieukin-6, or interferon-7 genes
34. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an anti-tumor responses
35. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity
36. Granulocyte-macrophage colony-stimulating factor as an adjuvant in tumor immunotherapy
37. Intraarterial delivery of adenovirus vectors and liposome-DNA complexes to experimental brain neoplasms
38. Rapid and efficient gene transfer in human hepatocytes by herpes viral vectors
39. Efficient gene transfer to human squamous cell carcinoma by the herpes simplex virus type1 amplicon vector
40. Oncolytic viral therapy for human colorectal cancer and liver metastases using a multi-mutated herpes simplex virus type-1 (G207)
41. An efficient deletion mutation packaging system for defective herpes simplex virus vectors: Potential applications to human gene therapy and neuronal physiology